December 20, 2025 – The Phase III clinical trial results of TenNor Therapeutics’ dual-acting drug, Rifasutenizol (TNP-2198), in a triple regimen as a first-line therapy for Helicobacter pylori infection, which were initially published online in September this year, have now been formally published in the inaugural issue of The Lancet Infectious Diseases 2026.

This Phase III clinical trial was a multicenter, randomized, double-blind, bismuth-containing quadruple therapy-controlled study conducted in China. Led by Professor Zhou Liya from Peking University Third Hospital, the trial covered 40 clinical centers across the country. The results demonstrated that the Rifasutenizol-based triple regimen, as a first-line therapy, exhibited multiple advantages over the current standard bismuth-containing quadruple therapy.

Rifasutenizol is the first new molecular entity specifically developed for Helicobacter pylori since its discovery over 40 years ago. Its multi-target synergistic mechanism is expected to overcome the resistance issues associated with traditional antibiotics, offering new treatment options for patients with Helicobacter pylori infection.

Media Contact:

Phone: +86 512-8686-1986

Email: info@tennorx.com or may.yang@h-advisors.global

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com